In this trial, DCs were silenced for SOCS1 expression (to prevent negative regulation of DCs), pulsed with survivin and MUC1 (heavily expressed proteins in NSCLC tumor), and flagellin (immune stimulant) [149,162]. The gene discussed is BIRC5; the disease is non-small cell lung carcinoma.